Contact information
+44 (0)1865 271883 (Pharm) 275643 (Chemistry)
Research groups
Colleges
Angela Russell
Professor of Medicinal Chemistry
- Bernard Taylor Fellow and Tutor in Organic Chemistry
My work focuses on the discovery of new drug targets and mechanisms, and the translation of these findings into new clinical candidates.
Through several successful multidisciplinary research collaborations, my team works in a range of therapeutic areas including identifying small molecules to upregulate utrophin for the treatment of Duchenne Muscular Dystrophy (DMD), new anti-cancer agents and agents to stimulate endogenous cell populations for regenerative medicine.
I have co-founded two spin-out companies to date, MuOx Ltd (acquired by Summit plc in November 2013), for the development of new small molecule utrophin modulators for DMD therapy, and OxStem Ltd, a company to translate our research findings in small molecule manipulation of stem cells for regenerative medicine. Most recently, OxStem Ltd raised a record £16.9M to identify new classes of drugs that can re-programme or stimulate existing endogenous cells to repair tissues in age-related conditions including cancer, neurodegenerative diseases and heart failure.
As well as my active teaching commitments within the Departments of Pharmacology and Chemistry and at St John’s College, I am a member of, and contribute to, the Oxford Stem Cell Institute (OSCI), the British Heart Foundation Centre of Research Excellence (BHF CRE), and the Cancer Research UK Oxford Centre – supporting at all levels including research and training.
Key publications
-
Structure-activity relationships and colorimetric properties of specific probes for the putative cancer biomarker human arylamine N-acetyltransferase 1.
Journal article
Egleton JE. et al, (2014), Bioorg Med Chem, 22, 3030 - 3054
-
Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists.
Journal article
Gianella-Borradori M. et al, (2015), Bioorg Med Chem, 23, 241 - 263
-
Stemistry: the control of stem cells in situ using chemistry.
Journal article
Davies SG. et al, (2015), J Med Chem, 58, 2863 - 2894
Recent publications
-
Statin-activation of RyR1 is a class effect but separable from HMG-CoA reductase inhibition.
Journal article
Lindsay C. et al, (2022), Br J Pharmacol
-
Recent Advances in Small Molecule Stimulation of Regeneration and Repair.
Journal article
Silpa L. et al, (2022), Bioorg Med Chem Lett
-
Structural Requirements for Dihydrobenzoxazepinone Anthelmintics: Actions against Medically Important and Model Parasites: Trichuris muris, Brugia malayi, Heligmosomoides polygyrus, and Schistosoma mansoni.
Journal article
Partridge FA. et al, (2021), ACS Infect Dis
-
Pilot Study to Quantify Palladium Impurities in Lead-like Compounds Following Commonly Used Purification Techniques
Journal article
Chatzopoulou M. et al, (2021), ACS Medicinal Chemistry Letters
-
Decreasing HepG2 Cytotoxicity by Lowering the Lipophilicity of Benzo[d]oxazolephosphinate Ester Utrophin Modulators.
Journal article
Chatzopoulou M. et al, (2020), ACS Med Chem Lett, 11, 2421 - 2427